Medical device companies are enhancing the clinical and commercial value of their products by adding active molecules.
Addition of an active typically extends the application of the device by improving the efficacy or safety. For example, addition of actives to cardiovascular stents has created great interest reducing the incidence of restenosis and creating a product category worth billions.
Developing drug-device combination products is often a major departure from the normal product development activity of these companies, indeed it presents major challenges.
We have significant track record in combination device developments working on behalf of the world’s leading cardiovascular stent, orthopaedics, dental and pharmaceutical companies.
Our experience of medical device, pharmaceutical and biologics development combined with our skills in engineering, chemistry, biochemistry, materials, coating, printing, polymers, nanotechnology, process development and regulatory compliance make us the ideal partner for developing combination products.
For help with developing combination products contact us on +44 1763 267492 or email healthcare@paconsulting.com
